Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Intravenous Immunoglobulin Market Heading Into 2029?

The market size for intravenous immunoglobulin has exhibited significant growth in the past few years. The forecast shows it will expand from $14.66 billion in 2024 to $15.57 billion in 2025, with a compound annual growth rate (CAGR) of 6.2%. This surge during the historic period can be attributed to its use in the treatment of primary immunodeficiency conditions, handling of neurological disorders, an increasing aging population, advancements in techniques for plasma fractionation, widened applications in neurology, and treatments for infectious diseases and pediatric immunodeficiency.

The market for intravenous immunoglobulin is forecasted to experience notable expansion in the coming years, with projections suggesting it will reach a value of $21.53 billion by 2029, with an 8.4% compound annual growth rate (CAGR). This expected increase over the forecast period is largely due to several factors, such as the increasing prevalence of autoimmune disorders, ongoing advancements in immunology research, a rise in healthcare spending, growing incidence of cancer, innovation in immunoglobulin products, and the rise of personalized medicine approaches. Key trends to look for during the forecast period include treatment developments for primary immunodeficiency disorders (PIDD), swift technological innovations, strategic alliances and partnerships, advancements in manufacturing procedures, neurological applications, uses in hematology, and developments in immunotherapy techniques.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8538&type=smp

Which Factors Are Pushing The Intravenous Immunoglobulin Market Forward?

The rise in the elderly population is projected to propel the advancement of the intravenous immunoglobulin market. The term “elderly population” pertains to individuals who are 65 years old and above. With advancing age, the immune system tends to malfunction and there is a scarcity of antibodies. Hence, these individuals require immunoglobulins to supply them with necessary antibodies. This escalated need fuels the demand for intravenous immunoglobulis and propels the intravenous immunoglobulin market. For example, projections from the Population Reference Bureau, a nonprofit organization based in Kenya, stated that by January 2024, the population of Americans aged 65 and older is set to increase from 58 million in 2022 to 82 million by 2050, marking a 47% rise. The proportion of this age bracket in comparison to the total population is also expected to grow from 17% to 23% within the same timeframe. Consequently, an uptick in the elderly population is anticipated to spur the expansion of the intravenous immunoglobulin market.

Which Segment Held The Largest Share In The Intravenous Immunoglobulin Market In 2025?

The intravenous immunoglobulin market covered in this report is segmented –

1) By Type: IgG (Immunoglobulin G), IgM (Immunoglobulin M), IgA (Immunoglobulin A), IgE (Immunoglobulin E), IgD (Immunoglobulin D)

2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels

3) By Application: Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Other Applications

4) By End-User: Hospitals, Clinics, Home Care

Subsegments:

1) By Immunoglobulin G (IgG): Normal IgG, Specific IgG

2) By Immunoglobulin M (IgM): Normal IgM, Specific IgM

3) By Immunoglobulin A (IgA): Normal IgA, Specific IgA

4) By Immunoglobulin E (IgE): Normal IgE, Specific IgE

5) By Immunoglobulin D (IgD): Normal IgD, Specific IgD

How Are Key Trends Driving Expansion In The Intravenous Immunoglobulin Industry?

Emerging as a major trend in the intravenous immunoglobulin market, product innovation is increasingly being prioritized by leading companies. These organizations are striving to introduce innovative new products such as liquid immune globulin treatments specifically for immunodeficiency conditions in order to solidify their market standing. For instance, GC Pharma, a pharmaceutical organization based in South Korea, launched an FDA-approved product named Alyglo in December 2023. This new solution is a sterile, pre-prepared liquid formulation comprising 10% immunoglobulin G (IgG), which delivers 100 mg/mL of protein, including a minimum of 96% human IgG acquired from collective human plasma. It is outlined specifically for treating primary humoral immunodeficiency (PI) in adults aged 17 years and above, targeting diseases like congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiency (SCID).

Which Organizations Are Driving Progress In The Intravenous Immunoglobulin Industry?

Major companies operating in the intravenous immunoglobulin market are Bio Products Laboratory Limited, Biotest AG, China Biologic Products Holdings Inc., CSL Behring, Grifols S.A., Kedrion SpA, Shanghai RAAS Blood Products Co. Ltd., Octapharma AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., LFB Biotechnologies SAS, BDI Pharma Inc., Hualan Biological Engineering Inc., ADMA Biologics Inc., Bharat Serums and Vaccines Limited, Sanquin Plasma Products B.V., Prothya Biosolutions B.V., Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., Pfizer Inc., Kedrion Biopharma, Intas Pharmaceuticals, Octapharma Pharmazeutika Produktionsges.m.b.H., GC Pharma, Grifols Biologicals Inc., Kamada Ltd., LFB USA, Octapharma Plasma Inc., Panacea Biotec Ltd.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/intravenous-immunoglobulin-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Intravenous Immunoglobulin Industry?

North America was the largest region in the intravenous immunoglobulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intravenous immunoglobulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8538&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model